▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | GreenCity | Italian Channel Awards | Italian Project Awards | ...
InnovationOpenLab

Leading AI-Powered Biopharma BPGbio Appoints Kenin Spivak to Board of Directors

BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrep...

Business Wire

BOSTON: BPGbio, Inc., the leading biology-first AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced the addition of Kenin M. Spivak, a highly regarded executive, entrepreneur, financier, author, and attorney to its Board of Directors, as an independent director.

“We are thrilled to welcome Kenin Spivak to the BPGbio Board,” said Daniel Elliott, Executive Chairman of BPGbio. “Kenin’s wealth of experience in multi-disciplinary business fields and expertise in corporate governance are invaluable assets to BPGbio as we as grow our business to the next level by advancing our late-stage therapeutic pipeline and strategic partnerships.”

Mr. Spivak is the founder, chairman and CEO of SMI Group LLC and chairman of its operating units. Prior to SMI Group, Mr. Spivak led multi-national companies with billions of dollars of worldwide sales and operations in more than 30 countries, including serving as CEO of a News Corporation affiliate, a wireless technology company, and distribution companies, principal operating officer of major studio MGM/UA, founding chairman of the Paul Mitchell cosmetology schools, and an officer and director of Merrill Lynch media and entertainment partnerships. He has served as a director of, and advisor to, several healthcare and technology companies.

“BPGbio is greatly accelerating the development of new therapeutics and diagnostics by uniting its pioneering scientific team, the nation’s leading biobank, and cutting-edge AI capabilities," said Mr. Spivak, adding, “I am honored to join the board and look forward to supporting BPG’s development and commercialization of its late-stage assets.”

Mr. Spivak received A.B., M.B.A. and J.D. degrees from Columbia University, each with honors, completing all three degrees in six years. He is admitted to practice law in California and New York, and holds numerous securities licenses, including Series 24 (general securities principal).

BPGbio's therapeutic pipeline, developed from the company’s NAi Interrogative Biology® Platform, includes therapeutic candidates being studied for glioblastoma multiforme (GBM) in active phase 2b, pancreatic cancer in phase 2a, epidermolysis bullosa (EB), squamous cell carcinoma (SCC), sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson's disease, and diabetes type II. The company's diagnostic pipeline includes its prostate diagnostic panel pstateDx, as well as tests being developed and validated for the detection of Parkinson’s disease, pancreatic cancer, breast cancer and liver disease.

About BPGbio, Inc.

BPGbio is the leading biology-first AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world's largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way disease is diagnosed and treated. For more information, visit www.bpgbio.com.

Contacts

media@bpgbio.com

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

Italy's Space Economy ecosystem looks to the Moon

Italian Space Agency is developing a lunar habitation module that could be used in the NASA Artemis Space exploration program

Bravo Innovation Hub Palermo: 20 startups selected for acceleration

The acceleration program developed by MIMIT selected the best startups for the “New energy, green and clean tech” and “Inclusion, social impact and Health”…

Italian system integrator Var Group expands digital security services…

With the acquisition of 51% of the South Tyrolean company ICS, the business unit Digital Security will also strengthen its Security Operation Center

Displaid selected by Bravo Innovation Hub

Displaid is a monitoring-as-a-Service startup that improves the management of infrastructure networks by identifying the types of damage in advance.

Most read

Italian system integrator Var Group expands digital security services…

With the acquisition of 51% of the South Tyrolean company ICS, the business unit Digital Security will also strengthen its Security Operation Center

Italy's Space Economy ecosystem looks to the Moon

Italian Space Agency is developing a lunar habitation module that could be used in the NASA Artemis Space exploration program

BrainChip Attracts Former Intel AI Sales Executive to Head Up Sales

BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic…

Bravo Innovation Hub Palermo: 20 startups selected for acceleration

The acceleration program developed by MIMIT selected the best startups for the “New energy, green and clean tech” and “Inclusion, social impact and Health”…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!